Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Recurrent Childhood Acute Lymphoblastic Leukemia Clinical Trial

Official title:

A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01445080
• Other study ID #: NCI-2009-00358
• Secondary ID: NCI-2009-0035806
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: May 30, 2006
• Est. completion date: December 10, 2012

Study information

• Verified date: January 2021
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I/II trial is studying the side effects and best dose of sorafenib in treating young patients with relapsed or refractory solid tumors or leukemia. Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.

Description:

PRIMARY OBJECTIVES: I. Determine the maximum-tolerated dose (MTD) and recommended phase II dose of sorafenib in pediatric patients with relapsed or refractory solid tumors. II. Determine whether pediatric patients with relapsed or refractory leukemia can tolerate the MTD of sorafenib for solid tumors. III. Determine the tolerability, active N-oxide metabolite, pharmacodynamics, and activity of sorafenib a the MTD in a subset of patients with acute myeloid leukemia (AML) and FLT3-ITD mutation. IV. Determine the toxicities of this drug in these patients. V. Determine the pharmacokinetics of this drug in these patients. SECONDARY OBJECTIVES: I. Determine, preliminarily, the antitumor activity of this drug within the confines of a phase I trial. II. Assess the biologic effect of sorafenib on circulating endothelial cells (CEC), circulating CEC precursors (CECP), VEGF, and VEGF-2 in peripheral blood. III. Assess the gene expression, proteomic profile, and ERK phosphorylation in blasts of patients with refractory leukemia treated with this regimen. IV. Assess the effect of sorafenib on solid tumor vascularity and tumor blood flow using dynamic contrast-enhanced MRI (DEMRI) in patients with measurable soft tissue tumors. V. Analyze tumor samples and leukemic blasts for the presence of ras, raf, or FLT3 (leukemias) mutations. VI. Analyze the plasma inhibitory activity for FLT3 phosphorylation in peripheral blood of patients with AML and FLT3-ITD mutation. VII. Determine the tolerability, pharmacokinetics of sorafenib and sorafenib?s active N-oxide metabolite, pharmacodynamics, and activity of sorafenib administered at the MTD for refractory leukemias in a subset of patients with AML and FLT3-ITD mutation. VIII. Analyze the plasma inhibitory activity for FLT3 phosphorylation in peripheral blood samples obtained at the time of PK studies in patients with FLT3-ITD mutation AML. OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to diagnosis (malignant solid tumor vs leukemia). STRATUM I(REFRACTORY SOLID TUMOR PATIENTS): Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of sorafenib until the maximum-tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity (DLT). Once the MTD is determined, up to 6 additional patients under 12 years of age may be treated at the MTD. The MTD dose level is also expanded to enroll up to 6 patients with refractory leukemia. STRATUM II (REFRACTORY LEUKEMIA PATIENTS): A cohort of 3-6 patients with leukemia receives treatment as in stratum 1 at the MTD determined in stratum 1. If 2 of 3 or 2 of 6 patients experience a DLT at the solid tumor MTD, sorafenib is reduced by one dose level. The leukemia MTD is defined as the dose at which < 1/3 of patients experience DLT during course 1 of treatment. STRATUM III (ACUTE MYELOID LEUKEMIA AND FLT3-ITD MUTATION PATIENTS): Patients receive sorafenib as in stratum 1 at the MTD determined in stratum 2. Patients undergo blood sample collection for pharmacokinetics, pharmacodynamics (in leukemia blasts only), circulating endothelial cells (CEC), circulating CEC precursors (CECP), VEGF and VEGF-2 , gene expression, proteomic profile, ERK phosphorylation, and FLT3 phosphorylation activity. Tumor tissue samples may also be analyzed for the presence of ras, raf, or FLT3. After completion of study treatment, patients are followed periodically.

Other known NCT identifiers

• NCT00343694
• NCT01648413

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: December 10, 2012
• Est. primary completion date: March 16, 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 21 Years

Eligibility

Inclusion Criteria:

• Diagnosis of 1 of the following:
• Histologically confirmed malignant solid tumor at original diagnosis or relapse
• Measurable or evaluable disease by CT scan or MRI
• Histologically confirmed leukemia, including 1 of the following:
• Acute lymphoblastic leukemia (ALL)
• Greater than 25% blasts in the bone marrow (M3 bone marrow)
• Acute myeloid leukemia (AML)
• Greater than 25% blasts in the bone marrow (M3 bone marrow)
• AML and FLT3-ITD mutation
• Patients must have ? 5% blasts in the bone marrow
• Active extramedullary disease (except leptomeningeal disease) allowed
• Juvenile myelomonocytic leukemia (JMML) meeting the following criteria:
• Peripheral blood monocytosis > 1,000/mm^3
• Blasts (including promonocytes) are < 20% of the WBCs in the blood and of the nucleated bone marrow cells
• No Philadelphia chromosome (Ph) or BCR/ABL fusion gene
• Has ? 2 of the following additional diagnostic criteria:
• Hemoglobin F increased for age
• Immature granulocytes in the peripheral blood
• WBC > 10,000/mm^3
• Clonal chromosomal abnormality (e.g., may be monosomy 7)
• Sargramostim (GM-CSF) hypersensitivity of myeloid progenitors in vitro
• Chronic myelogenous leukemia (CML) in blast crisis
• Greater than 25% blasts in the bone marrow (M3 bone marrow)
• Patients with Ph-positive CML must be refractory to imatinib mesylate
• Relapsed or refractory disease
• Patients with acute promyelocytic leukemia (APL) must be refractory to treatment with tretinoin and arsenic trioxide
• Standard curative therapies or therapies proven to prolong survival with an acceptable quality of life do not exist
• Active extramedullary disease, except active leptomeningeal leukemia, allowed
• No brain tumors or known brain metastases
• Karnofsky performance status (PS) 50-100% (for patients > 10 years of age)
• Lansky PS 50-100% (for patients ? 10 years of age)
• Patients with solid tumors must have adequate bone marrow function, as defined by the

following:

• Absolute neutrophil count ? 1,000/mm^3
• Platelet count ? 75,000/mm^3 (transfusion independent)
• Hemoglobin ? 8.0 g/dL (red blood cell [RBC] transfusions allowed)
• Patients with leukemia may have abnormal blood counts but must meet the following

criteria:

• Platelet count ? 20,000/mm^3 (platelet transfusions allowed)
• Hemoglobin ? 8.0 g/L (RBC transfusions allowed)
• Patients with acute myeloid leukemia and FLT3-ITD mutation
• Platelet count ? 20,000/mm^3
• Lipase and amylase normal
• Creatinine clearance or radioisotope glomerular filtration rate ? 70 mL/min OR

creatinine normal based on age as follows:

• No greater than 0.8 mg/dL (for patients 5 years of age and under)
• No greater than 1.0 mg/dL (for patients 6-10 years of age)
• No greater than 1.2 mg/dL (for patients 11-15 years of age)
• No greater than 1.5 mg/dL (for patients over 15 years of age)
• Patients with solid tumors must meet the following criteria:
• Bilirubin normal for age
• ALT normal for age (for the purpose of this study, the upper limit of normal [ULN] for ALT is 45 ?/L)
• Serum albumin ? 2 g/dL
• Patients with leukemia must meet the following criteria:
• Bilirubin (sum of conjugated + unconjugated) ? 1.5 times ULN for age
• ALT ? 5.0 times ULN for age (? 225 ?/L) (for the purpose of this study, the ULN for ALT is 45 ?/L)
• Serum albumin ? 2 g/dL
• Albumin ? 2 g/dL
• PT, PTT, and INR normal (for patients on prophylactic anticoagulation)
• No evidence of dyspnea at rest
• No exercise intolerance
• Pulse oximetry >94% on room air, if there is clinical indication for determination
• Diastolic blood pressure ? the 95th percentile for age and gender (height included for AML and FLT3-ITD mutation patients)
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No uncontrolled infection
• Able to swallow tablets
• No evidence of bleeding diathesis
• No other medical condition or situation that would preclude study compliance
• No known Gilbert syndrome
• Fully recovered from prior chemotherapy, immunotherapy, or radiotherapy (for patients with solid tumors)
• Recovered from the non-hematologic toxic effects of all prior therapy (for patients with leukemia)
• Recovered from acute non-hematologic toxic effects of all prior anti-cancer chemotherapy (for patients with AML and FLT3-ITD mutation)
• At least 7 days since prior hematopoietic growth factors
• At least 7 days since prior biologic agents
• At least 2 weeks since prior local palliative radiotherapy (small port)
• At least 3 months since prior total-body irradiation, craniospinal radiotherapy, or radiation to ? 50% of the pelvis
• At least 6 weeks since other prior substantial bone marrow radiation (e.g., skull, spine, pelvis, ribs)
• At least 3 months since prior stem cell transplantation or rescue (for patients with solid tumors)
• No evidence of active graft-vs-host disease
• At least 3 months since prior myeloablative therapy followed by bone marrow or stem cell transplantation (for patients with leukemia)
• At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) (for patients with solid tumors)
• At least 24 hours since prior nitrosoureas (for patients with AML and FLT3-ITD mutation)
• At least 2 weeks since prior chemotherapy (for patients with leukemia)
• At least 3 weeks since prior monoclonal antibody therapy
• No prior sorafenib
• No other concurrent investigational drugs
• No other concurrent anticancer agents or therapies, including chemotherapy, radiotherapy, immunotherapy, or biologic therapy
• Concurrent maintenance-like chemotherapy for patients with AML and FLT3-ITD mutation allowed
• No concurrent administration of any of the following:
• Cytochrome P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital)
• Rifampin
• Grapefruit juice
• Hypericum perforatum (St. John wort)
• No concurrent therapeutic anticoagulation
• Concurrent prophylactic anticoagulation (e.g., low-dose warfarin) of venous or arterial access devices allowed provided the requirements for PT, INR, or PTT are met

Related Conditions & MeSH terms

• Blastic Phase
• Childhood Acute Promyelocytic Leukemia With PML-RARA
• Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive
• Childhood Solid Neoplasm
• Chronic Myelogenous Leukemia, BCR-ABL1 Positive
• Juvenile Myelomonocytic Leukemia
• Leukemia
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid
• Leukemia, Myelomonocytic, Juvenile
• Leukemia, Promyelocytic, Acute
• Philadelphia Chromosome
• Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Recurrent Childhood Acute Lymphoblastic Leukemia
• Recurrent Childhood Acute Myeloid Leukemia
• Recurrent Disease

Intervention

Other:
• Laboratory Biomarker Analysis
Correlative studies
• Pharmacological Study
Correlative studies

Drug:
• Sorafenib Tosylate
Given orally

Locations

Country	Name	City	State
Canada	Centre Hospitalier Universitaire Sainte-Justine	Montreal	Quebec
Canada	Hospital for Sick Children	Toronto	Ontario
United States	C S Mott Children's Hospital	Ann Arbor	Michigan
United States	National Institutes of Health Clinical Center	Bethesda	Maryland
United States	University of Alabama at Birmingham Cancer Center	Birmingham	Alabama
United States	Dana-Farber Cancer Institute	Boston	Massachusetts
United States	Lurie Children's Hospital-Chicago	Chicago	Illinois
United States	Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio
United States	UT Southwestern/Simmons Cancer Center-Dallas	Dallas	Texas
United States	Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	Houston	Texas
United States	Indiana University/Melvin and Bren Simon Cancer Center	Indianapolis	Indiana
United States	Riley Hospital for Children	Indianapolis	Indiana
United States	St. Jude Children's Research Hospital	Memphis	Tennessee
United States	Children's Hospital of Wisconsin	Milwaukee	Wisconsin
United States	University of Minnesota/Masonic Cancer Center	Minneapolis	Minnesota
United States	Columbia University/Herbert Irving Cancer Center	New York	New York
United States	Children's Hospital of Orange County	Orange	California
United States	Lucile Packard Children's Hospital Stanford University	Palo Alto	California
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania
United States	Children's Hospital of Pittsburgh of UPMC	Pittsburgh	Pennsylvania
United States	Oregon Health and Science University	Portland	Oregon
United States	Washington University School of Medicine	Saint Louis	Missouri
United States	Seattle Children's Hospital	Seattle	Washington
United States	State University of New York Upstate Medical University	Syracuse	New York
United States	Children's National Medical Center	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Patients With Treatment-related Dose Limiting Toxicity in Cycle 1 by Dose Level	Number of patients with treatment-related dose limiting toxicities in cycle 1, as defined by study protocol, stratified by dose level.	Up to 28 days
Primary	Number of Patients With Treatment-related Adverse Events	Number of patients with treatment-related adverse events stratified by dose level through study completion.	Up to 2 years
Primary	Area Under the Plasma Concentration Versus Time Curve (AUC) of Sorafenib	Area under the plasma concentration versus time curve (AUC) of sorefenib administered orally as tablets, BID approximately every 12 hours for cycles of 28 days with no rest period between cycles to children with refractory solid tumors or leukemias.	During cycle 1 or cycle 2 after at least 14 consecutive days of sorafenib administration Pre-dose, 0.5, 1, 2, 3, 5, 8 hours post dose
Primary	Clearance (Cl) of Sorafenib	Clearance of sorefenib administered orally as tablets, BID approximately every 12 hours for cycles of 28 days with no rest period between cycles to children with refractory solid tumors or leukemias.	During cycle 1 or cycle 2 after at least 14 consecutive days of sorafenib administration Pre-dose, 0.5, 1, 2, 3, 5, 8 hours post dose
Primary	Half-life of Sorafenib	Half-life of sorefenib administered orally as tablets, BID approximately every 12 hours for cycles of 28 days with no rest period between cycles to children with refractory solid tumors or leukemias.	During cycle 1 or cycle 2 after at least 14 consecutive days of sorafenib administration Pre-dose, 0.5, 1, 2, 3, 5, 8 hours post dose
Primary	Maximum Serum Concentration (Cmax) of Sorafenib	Maximum serum concentration (Cmax) of sorefenib administered orally as tablets, BID approximately every 12 hours for cycles of 28 days with no rest period between cycles to children with refractory solid tumors or leukemias.	During cycle 1 or cycle 2 after at least 14 consecutive days of sorafenib administration Pre-dose, 0.5, 1, 2, 3, 5, 8 hours post dose
Primary	Number of Patients With Treatment-related Dose Limiting Toxicities in Later Cycles by Dose Level	Number of patients with treatment-related dose limiting toxicities in later cycles, as defined by study protocol, stratified by dose level.	Up to 2 years
Primary	Area Under the Plasma Concentration Versus Time Curve (AUC) of Sorafenib	Area under the plasma concentration versus time curve (AUC) of sorefenib administered orally as tablets, BID approximately every 12 hours for cycles of 28 days with no rest period between cycles to children with AML and FLT3-ITD mutation.	8 hours post dose on day 1 of cycle 1
Primary	Clearance (Cl) of Sorafenib	Clearance of Sorefenib administered orally as tablets, BID approximately every 12 hours for cycles of 28 days with no rest period between cycles to children with AML and FLT3-ITD mutation.	8 hours post dose on day 1 of cycle 1
Primary	Half-life of Sorafenib	Half-life of sorefenib administered orally as tablets, BID approximately every 12 hours for cycles of 28 days with no rest period between cycles to children with AML and FLT3-ITD mutation.	8 hours post dose on day 1 of cycle 1
Primary	Volume of Distribution at Steady State (Vss) of Sorafenib	Volume of distribution at steady state (Vss) of sorefenib administered orally as tablets, BID approximately every 12 hours for cycles of 28 days with no rest period between cycles to children with refractory solid tumors, leukemia, or AML and FLT3-ITD mutation.	8 hours post dose on day 1 of cycle 1
Primary	Maximum Serum Concentration (Cmax) of Sorafenib	Maximum serum concentration (Cmax) of Sorefenib administered orally as tablets, BID approximately every 12 hours for cycles of 28 days with no rest period between cycles to children with AML and FLT3-ITD mutation.	8 hours post dose on day 1 of cycle 1
Secondary	Number of Patients Who Respond Using RECIST Criteria	Frequency (%) of patients with Partial Response (PR) or Complete Response (CR) using the RECIST criteria by study part and dose level	Up to 2 years
Secondary	Mean Concentration of VEGF2	Mean concentration of VEGF2 in peripheral blood sample.	28 days
Secondary	Pharmacodynamics (PD) Blood Flow Part C	Pharmacodynamics: tumor blood flow in patients with AML and FLT3-ITD mutation using dynamic contrast enhanced MRI (DEMRI) (Part C).	1 week prior to enrollment, then every 28 days
Secondary	Number of Patients With DEMRI	Assess effect on tumor blood flow via DEMRI in patients with measurable soft tissue tumors.	Up to 2 years
Secondary	Leukemia Mutations	Analyze tumor samples and leukemic blasts from patients entered on this study for the presence of ras, raf, or FLT3 (leukemia) mutations.	1 week prior to enrollment
Secondary	Plasma Inhibitory Activity (PIA)	Analyze the plasma inhibitory activity (PIA) for FLT3 phosphorylation in peripheral blood samples obtained at the time of PK studies in patients with FLT3-ITD mutation AML (Part C).	1 week prior to enrollment and then every 28 days